Latest Breaking News On - Steven fruchtman - Page 1 : comparemela.com

Onconova Therapeutics (ONTX) to Merge with Trawsfynydd Therapeutics

Onconova Therapeutics (ONTX) to Merge with Trawsfynydd Therapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jacke stoverTorrey pinesSteven fruchtmanMark guerin onconovaMark guerinJames marinoBruce mackleC david pauzaSnell wilmerWerner cautreelsRobert redfieldHerrington sutcliffeNikolay savchukTrawsfynydd torrey pinesTrafford clarkeCompany contacts

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets Nineteenth Annual Emerging Growth Equity Conference

28.11.2023 - NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today .

Bruce mackleMark guerinSteven fruchtmanLifesci advisorsCompany contactOnconova management teamOnconova therapeutics incBreakout sessionNoble capital marketsNoble capital marketOnconova therapeuticsSci advisors

Onconova Therapeutics ASH Poster To Focus on Narazaciclib in MCL

Onconova Therapeutics ASH Poster To Focus on Narazaciclib in MCL
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diego convention centerComunidad autonoma de catalunaSan diegoNuria profitos pelejaSteven fruchtmanBruce mackle lifesci advisorsOnconova therapeutics incAmerican society for hematology annual meeting expositionMark guerinonconova therapeutics incLymphoma translational groupSecurities exchangeCompany contactJosep carreras leukaemia research instituteAmerican societyHematology annual meeting

Onconova Therapeutics ASH Poster To Focus on Narazaciclib in MCL Seite 1

02.11.2023 - Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: . Seite 1

Comunidad autonoma de catalunaSteven fruchtmanJosep carreras leukaemia research institute

Onconova Therapeutics ASH Poster To Focus on Narazaciclib in MCL -November 02, 2023 at 10:38 am EDT

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 .

San diegoUnited statesSan diego convention centerComunidad autonoma de catalunaBruce mackleMark guerinNuria profitos pelejaSteven fruchtmanCompany contactAmerican society for hematology annual meeting expositionJosep carreras leukaemia research instituteGlobenewswire incOnconova therapeutics incSecurities exchangeLymphoma translational groupLifesci advisors